Trial-Results center  
Clinical trial results database in cardiology Feedback    Home

Systematic review and meta-analysis

This trial is included in the following systematic reviews and meta-analyses:

percutaneous coronary intervention - anticoagulant - all type of patients

percutaneous coronary intervention - antithrombotics - all type of patients


Related trials

ATOLL, 2010 - enoxaparin vs standard heparin

NAPLES (Tavano), 2009 - bivalirudin vs actionated heparin plus tirofiban

CHAMPION-PCI, 2009 - cangrelor up front vs clopidogrel up front

CHAMPION-PLATFORM, 2009 - cangrelor up front vs delayed clopidogrel

TRA-PCI, 2009 - SCH 530348 vs placebo

HORIZONS-AMI (Stone), 2008 - bivalirudin vs heparin + GP2b3a inhibitors

ISAR-REACT 3, 2008 - bivalirudin vs UFH

Hull, 2006 - extended tinzaparin vs standard treatment

INTERACT, 2006 - enoxaparin vs UFH (on top of aspirin)

Deitcher, 2006 - extended enoxaparin vs standard treatment

ACUITY (Stone) (bivalirudin alone), 2006 - bivalirudin vs heparin + GP2b3a inhibitors

STEEPLE, 2006 - enoxaparin vs UFH

Wells (subgroup), 2005 - tinzaparin vs dalteparin

Daskalopoulos, 2005 - LMWH at home vs UFH in hospital

Chong, 2005 - LMWH at home vs UFH in hospital

JUMBO-TIMI 26, 2005 - prasugrel vs clopidogrel

EVET, 2005 - enoxaparin vs tinzaparin

REPLACE-1, 2004 - bivalirudin vs UFH

Ramacciotti, 2004 - LMWH at home vs UFH in hospital

THE-PRINCE (Kleber), 2003 - enoxaparin vs UFH

REPLACE-2, 2003 - bivalirudin vs hepatin + anti Gp2b3a

Natarajan (without antiGp2b3a), 2003 - Dalteparin vs UFH

Cesarone, 2003 - extended enoxaparin vs standard treatment

CRUISE, 2003 - Enoxaparin vs UFH

Natarajan (+ antiGp2b3a), 2003 - Dalteparin vs UFH + anti Gp2b3a



See also:

  • All percutaneous coronary intervention clinical trials
  • All clinical trials of antithrombotics
  • All clinical trials of Enoxaparin
    		•  

    Galeote study, 2001

    download pdf: Enoxaparin | antithrombotics for percutaneous coronary intervention

    Treatments

    Studied treatment Enoxaparin 0.75 mg/kg bolus
    Control treatment UFH 70 U/kg bolus, then titrated to ACT > 200
    Concomittant treatment Abciximab

    Patients

    Patients PTCA patients with stable/unstable angina or AMI

    Method and design

    Randomized effectives 50 / 49 (studied vs. control)


    Results

    Endpoint Studied treat.
    n/N     Control treat.
    n/N     Graph RR [95% CI]

    Bleeding

    1 / 50
         4 / 49
         classic 0,25 [0,03;2,12]

    MACE

    5 / 50
         3 / 49
         classic 1,63 [0,41;6,47]     0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial    		 Ref
    Studied treat. Control treat.
    Bleeding 1 / 50 (2,0%) 4 / 49 (8,2%) 0,25 [0,03;2,12]
    MACE 5 / 50 (10,0%) 3 / 49 (6,1%) 1,63 [0,41;6,47]
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:

    Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    Bleeding 2,00% 8,16% -61,6‰
    MACE 10,00% 6,12% 3,9%

    Meta-analysis of all similar trials:

    anticoagulant in percutaneous coronary intervention for all type of patients

    antithrombotics in percutaneous coronary intervention for all type of patients



    Reference(s)

    Trials register # NA
    • Galeote G, Hussein M, Sobrino N, Calvo L, Yunda H, Sa�nchez-. Combination abciximab and enoxaparin or unfractionated heparin during percutaneous coronary intervention: a randomised study. Eur Heart J 2001;22(Suppl):663
      Pubmed | Hubmed | Fulltext

    (c) 2004-2011 TrialResults-center - All Rights Reserved

    Tweet this  |  Facebook  |  notify a friend